MedTrace Logo

Study of XB010 in Subjects With Solid Tumors

NCT06545331 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2026-04-15

No results posted yet for this study

Summary

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Conditions

  • Locally Advanced or Metastatic Solid Tumors
  • Esophageal Squamous Cell Cancer
  • Head and Neck Squamous Cell Cancer
  • NSCLC (Non-small Cell Lung Cancer)
  • Hormone-receptor-positive Breast Cancer
  • Triple Negative Breast Cancer (TNBC)

Interventions

DRUG

XB010

IV administration of XB010

DRUG

Pembrolizumab

IV administration of Pembrolizumab

Sponsors & Collaborators

Principal Investigators

  • Study Director · Exelixis

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-06
Primary Completion
2026-11-23
Completion
2027-10-20
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06545331 on ClinicalTrials.gov